Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taysha Gene TherapiesTSHA -2.71%33 PS Ratio is 334.67 as of Sep. 12, 2026, which is 674% above its 10-year median of 43.26. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 936 Biotechnology companies, Taysha Gene Therapies ranks worse than 91.67% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Taysha Gene Therapies's share price is $5.02.
Taysha Gene Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.02. Hence, Taysha Gene Therapies's PS Ratio for today is 334.67.
The historical rank and industry rank for Taysha Gene Therapies's PS Ratio or its related term are showing as below:
TSHA'
s PS Ratio Range Over the Past 10 Years
Min: 4.13 Med: 43.26 Max: 437.33
Current: 334.67
During the past 7 years, Taysha Gene Therapies's highest PS Ratio was 437.33. The lowest was 4.13. And the median was 43.26.
TSHA's PS Ratio is ranked worse than 91.67% of 936
companies
in the Biotechnology industry
Industry Median: 9.495
vs TSHA: 334.67
During the past 7 years, Taysha Gene Therapies's highest 3-Year average Revenue per Share Growth Rate was -18.40% per year. The lowest was -18.40% per year. And the median was -18.40% per year.
Taysha Gene Therapies (NAS:TSHA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Taysha Gene Therapies's Share Price of today is $5.02. Taysha Gene Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Taysha Gene Therapies (TSHA) has a PS Ratio of 334.67 as of Sep. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Taysha Gene Therapies and its competitors. This is 674% above median its historical median of 43.26. Over the past decade, Taysha Gene Therapies' PS Ratio has ranged from 4.13 to 437.33. According to the industry distribution chart, Taysha Gene Therapies ranks #858 out of 936 companies in the Biotechnology industry, placing it in the top 91.7%.
Is Taysha Gene Therapies' PS Ratio too high?
Taysha Gene Therapies' current PS Ratio of 334.67 is 674% above median its 10-year median of 43.26. Over the past 10 years, this metric has ranged from a low of 4.13 to a high of 437.33. The Biotechnology industry median PS Ratio is 9.50. Taysha Gene Therapies' value of 334.67 is 3424.7% above this industry median. Based on the distribution chart, Taysha Gene Therapies ranks #858 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' PS Ratio compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #858 out of 936 companies for PS Ratio. This places Taysha Gene Therapies in the lower half of its industry. The industry median PS Ratio is 9.50. Taysha Gene Therapies' value of 334.67 is 3424.7% above this benchmark. Historically, Taysha Gene Therapies' own PS Ratio has ranged from 4.13 to 437.33 over the past decade. While the company's 10-year median is 43.26 vs. the industry median of 9.50, Taysha Gene Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taysha Gene Therapies's current PS Ratio of 334.67 is 3424.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Taysha Gene Therapies and its competitors. For the Biotechnology industry, the median PS Ratio is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current PS Ratio is 334.67, which is 674% above median its own 10-year median of 43.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current PS Ratio is 334.67, which is 674% above median its 10-year median of 43.26 and 3424.7% above the Biotechnology industry median of 9.50. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current PS Ratio is 334.67 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
PS Ratio: 334.67 (674% above median its 10-year median of 43.26)
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
Industry Position: 3424.7% above the Biotechnology median (#858 of 936)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
